{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-23-000156","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.809645+00:00","generated_at":"2026-06-18T09:02:17.490848+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical reports 19% revenue growth in 2022, guides 17-20% growth for 2023","bullets":["Q4 2022 revenue $7.34M (+13.2% YoY); FY2022 revenue $27.9M (+18.8% YoY).","FY2022 net loss $8.6M ($0.19 loss per share) vs $4.6M loss in 2021.","Novel Therapies revenue grew 329.8% to $2.5M; Core business grew 11%.","Cash $17.4M at year-end; 2023 guidance: revenue $32.5-$33.5M (17-20% growth), gross margins 58-60%, cash >$10M.","Expects 6 new Novel Therapies collaborations and two 510(k) filings in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-23-000156","json":"https://secwatch.observer/filing/0001161697-23-000156.json","markdown":"https://secwatch.observer/filing/0001161697-23-000156.md","text":"https://secwatch.observer/filing/0001161697-23-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/0001161697-23-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:02:17.490848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25e6184216fc4d5503881f926462385e87e60764","claim":"KORU Medical Systems, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $7.3 million, net income Net loss for the fourth quarter of 2022 was $ 2.0 million, EPS $(0.04) per diluted share. Guidance raised.","evidence_excerpt":"fourth quarter and full year ended December 31, 2022. The Company also issued guidance for the full year 2023. Recent Highlights: ● Fourth quarter net revenue growth of 13% to $7.3 million, marking the fifth consecutive quarter of double-digit growth, and full year net revenue growth of 19% to $27.9 million ● Novel Therapies business finished the year with 14 total","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/0001161697-23-000156-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$7.3 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $ 2.0 million"},{"label":"EPS","value":"$(0.04) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}